Oncology

Latest News

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com

Patient Navigation Is Nonnegotiable in Cancer Care

By Maggie L. Shaw

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 23rd 2017

Healthcare Costs and Utilization After First-Line Therapy for Medicare DLBCL Patients

Christina Mattina

Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who relapsed following first-line treatment had higher rates of healthcare utilization and greater costs than the patients who had not relapsed.

January 23rd 2017

American Society of Hematology's Tenets for Hematologists to Choose Wisely

Surabhi Dangi-Garimella, PhD

Initiated by the American Board of Internal Medicine, Choosing WiselyÂ® is a campaign that has seen participation by a number of different national medical organizations to promote conversations between clinicians and patients to ensure adequate, evidence-based care.

Dr Sean Khozin on FDA Initiative to Analyze Data From Real-World Pipelines

January 23rd 2017

Dr Sean Khozin on FDA Initiative to Analyze Data From Real-World Pipelines

The Information Exchange and Data Transformation initiative at the FDA uses oncology data from not only clinical trials but also electronic health records and biosensors. This patient-centered approach brings research to the real world, as many oncology patients are excluded from clinical trials, said Sean Khozin, MD, MPH, senior medical officer at the FDA.

Jonathan Hirsch Discusses Challenges in Health IT Implementation

January 21st 2017

Jonathan Hirsch Discusses Challenges in Health IT Implementation

The state of current software systems, primarily electronic medical records, is a significant barrier to implementing successful health IT tools, said Jonathan Hirsch, founder and president of Syapse. He also explained some of the solutions developed by Syapse to address these challenges, like improving the software’s integration capabilities and making it more usable for providers.

January 20th 2017

Dr Richard Pazdur Confirmed Director of FDA's Oncology Center of Excellence

Surabhi Dangi-Garimella, PhD

Outgoing FDA Commissioner Robert Califf, MD, has announced that Richard Pazdur, MD, who was serving as the interim director, will now be heading the Oncology Center of Excellence.

This Week in Managed Care: January 20, 2017

January 20th 2017

This Week in Managed Care: January 20, 2017

This week, the top managed care stories included news that Republicans will introduce legislation to replace the Affordable Care Act, a report found the abortion rate hit a historic low, and results showed Januvia is safe for the oldest patients, even if they have cardiovascular risk.

January 20th 2017

ASH "Choosing Wisely Champions" Share Their Practice-Changing Success

Surabhi Dangi-Garimella, PhD

At the 2016 annual meeting, the American Society of Hematology introduced the “Choosing Wisely Champions” to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

January 20th 2017

Precision Genomic Panels a Vital Clinical Support Tool in Pediatric Brain Tumors

Surabhi Dangi-Garimella, PhD

A collaborative study has concluded that genomic assays can be successfully used to identify diagnostic, prognostic, and treatment-relevant alterations and can help guide precision treatment decisions for pediatric brain tumors.

January 18th 2017

Prior Ibrutinib Treatment Improves CAR T-Cell Expansion, Could Impact Response in CLL

Surabhi Dangi-Garimella, PhD

The improved expansion of chimeric antigen receptor (CAR) T-cells indicates a deeper clinical response.

January 18th 2017

Getting Insured Could Reduce Cancer-Related Deaths Among Minorities

Surabhi Dangi-Garimella, PhD

A new report released by the American Cancer Society indicates that while the cancer-related death rate was higher among blacks than in whites in 2014, the racial gap could reduce as minority patients increasingly gain access to insurance and subsequent healthcare.

January 18th 2017

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD

Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to present a favorable response to single-agent ibrutinib at a follow-up of 29 months.

January 18th 2017

Phase 3 GALLIUM Study Shows Promising Results With Obinutuzumab for Follicular Lymphoma

Christina Mattina

The results showed that obinutuzumab-based immunochemotherapy and maintenance improved progression-free survival in treatment-naÃ¯ve patients with follicular lymphoma.

January 18th 2017

Ibrutinib Prevents Cytokine-Release Syndrome After CAR T-Cell Therapy for B-Cell Neoplasms

Christina Mattina

A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib.

Dr Stuart Goldberg Explains Differences Between COTA and Traditional Data Analysis Tools

January 18th 2017

Dr Stuart Goldberg Explains Differences Between COTA and Traditional Data Analysis Tools

Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

January 17th 2017

MYSTIC Trial, Evaluating Durvalumab as First-Line in NSCLC, Adds OS Endpoint

Surabhi Dangi-Garimella, PhD

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

January 16th 2017

Cisplatin-Based Chemotherapy Increases Risk of Venous Thromboembolism

According to a new study, in addition to tumor type, stage, and the presence of comorbidities, patients receiving cisplatin-based treatments might be at an increased risk of venous thromboembolism.

January 16th 2017

The Value of Survival Gains in Myelodysplastic Syndromes

Joanna P. MacEwan, PhD Wes Yin, PhD Satyin Kaura, MSci, MBA Zeba M. Khan, PhD

This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.

January 16th 2017

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

Surabhi Dangi-Garimella, PhD

At the 58th American Society of Hematology Annual Meeting & Exposition, Jan Joseph Melenhorst, PhD, presented results of a study evaluating biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

January 16th 2017

Phase 3 LyMa Trial: Rituximab After ASCT Increases OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD

Phase 3 results from the LyMa trial have shown that rituximab, after autologous stem cell transplant (ASCT), prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL) following ASCT.

January 16th 2017

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

Surabhi Dangi-Garimella, PhD

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment plan of patients with mantle cell lymphoma can help overcome resistance to ibrutinib.

January 16th 2017

CAR-T Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR)-T cells of defined composition can be administered with an acceptable early toxicity.

January 16th 2017

Patient and Provider Education on Pain in Cancer: A Cost-Saving Intervention

Surabhi Dangi-Garimella, PhD

An experiment by Park Nicollet Health Services to document personalized pain management goals for patients in oncology clinics lowered documented pain, while physician education on cost information helped reduce treatment costs.

Dr Robert Carlson on Balancing Efficiency and Patient-Centered Care

January 16th 2017

Dr Robert Carlson on Balancing Efficiency and Patient-Centered Care

Oncologists need to ask patients the right questions and truly listen to the answers, but they must then balance the individuals’ goals with the practice’s efforts to provide consistently efficient cancer care to all patients, according to Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network.

January 15th 2017

Will Absence of Certain Cancer Centers on Insurance Exchanges Impact Outcomes?

Surabhi Dangi-Garimella, PhD

A new study conducted at The University of Texas has found that a majority of federal exchanges do not include National Cancer Institute-designated cancer centers.

David Fabrizio Suggests Advantages of Genomic Profiling for Payers

January 14th 2017

David Fabrizio Suggests Advantages of Genomic Profiling for Payers

Payers have been slow to adopt new technologies, but they are starting to be more proactive in seeking out genomic profiling companies, according to David Fabrizio, of Foundation Medicine, Inc. These molecular diagnostic tools make the healthcare process more efficient by performing a comprehensive test at the point of diagnosis.

This Week in Managed Care: January 13, 2017

January 13th 2017

This Week in Managed Care: January 13, 2017

This week, the top stories in managed care were that the Senate began the process of repealing the Affordable Care Act, Cigna and CVS moved away from the EpiPen, and the NCI Formulary will make it easier to study cancer drugs and their combinations.

January 13th 2017

Trump Administration Can Use ASCO's Principles to Ensure Healthcare Remains Patient-Centered

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology (ASCO) hopes that the principles will help ensure access to healthcare and adequate insurance, to improve outcomes among those diagnosed with cancer.

January 12th 2017

The Burden of Being a Medicare Patient With NSCLC

Surabhi Dangi-Garimella, PhD

Research published in the Journal of Oncology Practice has identified high treatment burden among Medicare patients with early-stage non—small cell lung cancer (NSCLC).

January 12th 2017

Joint Statement by 69 Cancer Centers Supports CDC's HPV Vaccination Guideline

Surabhi Dangi-Garimella, PhD

A conglomerate of 69 National Cancer Institute—designated cancer centers has come together to endorse the CDC’s recommendations for HPV vaccination of young children.

January 11th 2017

NCI Formulary a Big Support for Cancer Moonshot

Surabhi Dangi-Garimella, PhD

Described as a public—private partnership between the National Cancer Institute (NCI) and pharmaceutical and biotechnology companies, the NCI Formulary is expected to provide researchers rapid access to anticancer drugs for use in clinical trials.

...

82 83 84 85 86 87 88 89 90

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions